Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 725

1.

Venous thromboembolism prophylaxis in thoracic surgery patients: an international survey.

Shargall Y, Brunelli A, Murthy S, Schneider L, Minervini F, Bertolaccini L, Agzarian J, Linkins LA, Kestenholz P, Li H, Rocco G, Girard P, Venuta F, Samama M, Scarci M, Anraku M, Falcoz PE, Kirk A, Solli P, Hofstetter W, Okumura M, Douketis J, Litle V.

Eur J Cardiothorac Surg. 2019 Jul 30. pii: ezz191. doi: 10.1093/ejcts/ezz191. [Epub ahead of print]

PMID:
31363740
2.

Sex differences in mandibular repositioning device therapy effectiveness in patients with obstructive sleep apnea syndrome.

Vecchierini MF, Attali V, Collet JM, d'Ortho MP, Goutorbe F, Kerbrat JB, Leger D, Lavergne F, Monaca C, Monteyrol PJ, Morin L, Mullens E, Pigearias B, Martin F, Khemliche H, Lerousseau L, Meurice JC; ORCADES investigators, Abedipour D, Allard-Redon A, Aranda A, Attali V, Bavozet F, Becu M, Beruben W, Bessard J, Bonafe I, Boukhana M, Chabrol B, Chatte G, Lebret C, Collet JM, Coste O, Dumont N, Durand-Amat S, D'ortho MP, Elbaum JM, De Santerre OG, Goutorbes F, Grandjean T, Guyot W, Hammer D, Havasi C, Huet P, Kerbrat JB, Khemliche H, Koltes C, Leger D, Lacassagne L, Laur X, Lerousseau L, Liard O, Loisel C, Longuet M, Mallart A, Martin F, Merle Beral F, Meurice JC, Mokhtari Z, Monaca C, Monteyrol PJ, Muir JF, Mullens E, Muller D, Paoli C, Petit FX, Pigearias B, Pradines M, Prigent A, Putterman G, Rey M, Samama M, Tamisier R, Tiberge M, Tison C, Tordjman F, Triolet B, Vacher C, Vecchierini MF, Verain A.

Sleep Breath. 2019 Sep;23(3):837-848. doi: 10.1007/s11325-018-1766-8. Epub 2018 Dec 22.

3.

Mandibular lymphoma.

Vo Quang S, Sicard L, Samama M, Benslama L, Goudot P.

J Stomatol Oral Maxillofac Surg. 2018 Feb;119(1):49-51. doi: 10.1016/j.jormas.2017.10.004. Epub 2017 Oct 9.

PMID:
29024750
4.

Hyperplasie gingivale d’origine médicamenteuse.

Taelman G, Guyon A, Corchia A, Samama M, Roche Y.

Rev Prat. 2016 Nov;66(9):981. French. No abstract available.

PMID:
30512365
5.

[Pyogenic granuloma].

Guyon A, Samama M, Milliez S, Dridi SM, Gaultier F.

Rev Prat. 2015 Apr;65(4):471. French. No abstract available.

PMID:
26058182
6.

[Non-VKA oral anticoagulants: an update for the clinical biologists].

Mullier F, Douxfils J, Tamigniau A, Dogné JM, Horellou MH, Flaujac C, Chatelain B, Goffinet C, Samama MM, Gouin-Thibault I.

Ann Biol Clin (Paris). 2015 May-Jun;73(3):333-44. doi: 10.1684/abc.2015.1025. Review. French.

7.

[Abcès migrateur de Chompret-L'Hirondel abscess].

Samama M, Guyon A, Millez S, Myriam Dridi S, Gaultier F.

Rev Prat. 2014 Oct;64(8):1047. French. No abstract available.

PMID:
25510120
8.

Ex vivo reversal of the anticoagulant effects of edoxaban.

Halim AB, Samama MM, Mendell J.

Thromb Res. 2014 Oct;134(4):909-13. doi: 10.1016/j.thromres.2014.07.036. Epub 2014 Aug 7.

9.

Pharmacology and laboratory testing of the oral Xa inhibitors.

Samama MM, Meddahi S, Samama CM.

Clin Lab Med. 2014 Sep;34(3):503-17. doi: 10.1016/j.cll.2014.06.009. Epub 2014 Jul 25. Review.

PMID:
25168939
10.

[Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].

Meddahi S, Samama MM.

J Mal Vasc. 2014 May;39(3):183-94. doi: 10.1016/j.jmv.2014.02.001. Epub 2014 Mar 18. Review. French.

PMID:
24650612
11.

Prevention and treatment of venous thromboembolism--International Consensus Statement.

Nicolaides AN, Fareed J, Kakkar AK, Comerota AJ, Goldhaber SZ, Hull R, Myers K, Samama M, Fletcher J, Kalodiki E, Bergqvist D, Bonnar J, Caprini JA, Carter C, Conard J, Eklof B, Elalamy I, Gerotziafas G, Geroulakos G, Giannoukas A, Greer I, Griffin M, Kakkos S, Lassen MR, Lowe GD, Markel A, Prandoni P, Raskob G, Spyropoulos AC, Turpie AG, Walenga JM, Warwick D.

Int Angiol. 2013 Apr;32(2):111-260.

PMID:
24402349
12.

Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients. Subgroup analysis from the EXCLAIM randomised trial.

Yusen RD, Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Chen M, Deslandes B, Turpie AG.

Thromb Haemost. 2013 Dec;110(6):1152-63. doi: 10.1160/TH13-02-0170. Epub 2013 Oct 2.

PMID:
24085227
13.

[Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013].

Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, Rosencher N, Schved JF, de Maistre E, Samama MM, Mismetti P, Sié P.

Ann Fr Anesth Reanim. 2013 Oct;32(10):691-700. doi: 10.1016/j.annfar.2013.04.016. Epub 2013 Aug 30. Review. French. Erratum in: Ann Fr Anesth Reanim. 2014 Mar;33(3):198-9.

PMID:
23993157
14.

Laboratory assessment of rivaroxaban: a review.

Samama MM, Contant G, Spiro TE, Perzborn E, Le Flem L, Guinet C, Gourmelin Y, Rohde G, Martinoli JL.

Thromb J. 2013 Jul 3;11(1):11. doi: 10.1186/1477-9560-11-11.

15.

Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.

Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, Rosencher N, Schved JF, de Maistre E, Samama MM, Mismetti P, Sié P; Working Group on Perioperative Haemostasis.

Arch Cardiovasc Dis. 2013 Jun-Jul;106(6-7):382-93. doi: 10.1016/j.acvd.2013.04.009. Epub 2013 Jun 25.

16.

[Hemorrhagic accidents of the new oral anticoagulants and coagulation assays].

Samama MM, Conard J, Lillo-Le Louët A.

J Mal Vasc. 2013 Jul;38(4):259-70. doi: 10.1016/j.jmv.2013.05.005. Epub 2013 Jun 20. French.

PMID:
23790307
17.

Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assays.

Lindhoff-Last E, Ansell J, Spiro T, Samama MM.

Ann Med. 2013 Sep;45(5-6):423-9. doi: 10.3109/07853890.2013.801274. Epub 2013 Jun 7. Review.

PMID:
23746003
18.

The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor.

Mendell J, Lee F, Chen S, Worland V, Shi M, Samama MM.

J Cardiovasc Pharmacol. 2013 Aug;62(2):212-21. doi: 10.1097/FJC.0b013e3182970991.

PMID:
23615159
19.

Monitoring plasma levels of factor Xa inhibitors: how, why and when?

Samama MM, Amiral J, Guinet C, Le Flem L, Seghatchian J.

Expert Rev Hematol. 2013 Apr;6(2):155-64. doi: 10.1586/ehm.13.11. Review.

PMID:
23547865
20.

Which test to use to measure the anticoagulant effect of rivaroxaban: the anti-factor Xa assay.

Samama MM.

J Thromb Haemost. 2013 Apr;11(4):579-80. doi: 10.1111/jth.12165. No abstract available.

21.

Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study.

Samama MM, Guinet C, Le Flem L, Ninin E, Debue JM.

J Thromb Thrombolysis. 2013 Feb;35(2):140-6. doi: 10.1007/s11239-012-0803-x.

PMID:
23335022
22.

Venous thromboembolism risk in ischemic stroke patients receiving extended-duration enoxaparin prophylaxis: results from the EXCLAIM study.

Turpie AG, Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Chen M, Yusen RD; EXCLAIM Investigators.

Stroke. 2013 Jan;44(1):249-51. doi: 10.1161/STROKEAHA.112.659797. Epub 2012 Nov 1.

PMID:
23117723
23.

Do new oral anticoagulants require laboratory monitoring? The clinician point of view.

Samama MM, Guinet C, Le Flem L.

Thromb Res. 2012 Oct;130 Suppl 1:S88-9. doi: 10.1016/j.thromres.2012.08.286.

PMID:
23026675
24.

Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban.

Harenberg J, Marx S, Weiss C, Krämer R, Samama M, Schulman S; Subcommittee on Control of Anticoagulation of the ISTH.

J Thromb Haemost. 2012 Jul;10(7):1433-6. doi: 10.1111/j.1538-7836.2012.04784.x. No abstract available.

25.

Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation.

Lillo-Le Louët A, Wolf M, Soufir L, Galbois A, Dumenil AS, Offenstadt G, Samama MM.

Thromb Haemost. 2012 Sep;108(3):583-5. doi: 10.1160/TH12-03-0149. Epub 2012 Jul 10. No abstract available.

PMID:
22782645
26.

Massive transfusion: an overview of the main characteristics and potential risks associated with substances used for correction of a coagulopathy.

Seghatchian J, Samama MM.

Transfus Apher Sci. 2012 Oct;47(2):235-43. doi: 10.1016/j.transci.2012.06.001. Epub 2012 Jul 5. Review.

PMID:
22770808
27.

[Anticoagulant therapeutics: In order not to jeopardize a potential therapeutical progress].

Samama MM.

Presse Med. 2012 Jun;41(6 Pt 1):557-9. doi: 10.1016/j.lpm.2012.03.002. Epub 2012 Apr 24. French. No abstract available.

PMID:
22534134
28.

Pro- and anti-angiogenic agents.

Bridoux A, Mousa SA, Samama MM.

J Mal Vasc. 2012 Jun;37(3):132-9. doi: 10.1016/j.jmv.2012.02.002. Epub 2012 Apr 9. Review.

PMID:
22494976
29.

[Skin necrosis during long-term fluindione treatment revealing protein C deficiency].

Merklen-Djafri C, Mazurier I, Samama MM, Alhenc-Gelas M, Tortel MC, Cribier B, Roth B, Batard ML.

Ann Dermatol Venereol. 2012 Mar;139(3):199-203. doi: 10.1016/j.annder.2011.12.018. Epub 2012 Jan 30. French.

PMID:
22401685
30.

Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial.

Samama MM, Contant G, Spiro TE, Perzborn E, Flem LL, Guinet C, Gourmelin Y, Martinoli JL; Rivaroxaban Prothrombin Time Field Trial Laboratories.

Clin Appl Thromb Hemost. 2012 Mar-Apr;18(2):150-8. doi: 10.1177/1076029611426282. Epub 2012 Mar 2.

PMID:
22387577
31.

Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Garcia DA, Baglin TP, Weitz JI, Samama MM.

Chest. 2012 Feb;141(2 Suppl):e24S-e43S. doi: 10.1378/chest.11-2291. Review. Erratum in: Chest. 2012 May;141(5):1369. Dosage error in article text. Chest. 2013 Aug;144(2):721. Dosage error in article text.

32.
33.

Primary malignant lymphoma of the uterus: a case report and review of the literature.

Samama M, van Poelgeest M.

Case Rep Oncol. 2011 Sep;4(3):560-3. doi: 10.1159/000334852. Epub 2011 Dec 2.

34.

Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls.

Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, Le Flem L, Rohde G, Martinoli JL; Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories.

Thromb Haemost. 2012 Feb;107(2):379-87. doi: 10.1160/TH11-06-0391. Epub 2011 Dec 21.

PMID:
22187012
35.

Risk assessment models for thromboprophylaxis of medical patients.

Samama MM, Combe S, Conard J, Horellou MH.

Thromb Res. 2012 Feb;129(2):127-32. doi: 10.1016/j.thromres.2011.09.025. Epub 2011 Nov 1. Review. No abstract available.

PMID:
22047755
36.

Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban.

Gerotziafas GT, Baccouche H, Sassi M, Galea V, Chaari M, Hatmi M, Samama MM, Elalamy I.

Thromb Res. 2012 Jan;129(1):101-3. doi: 10.1016/j.thromres.2011.09.004. Epub 2011 Oct 13. No abstract available.

PMID:
22000405
37.

In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.

Samama MM, Mendell J, Guinet C, Le Flem L, Kunitada S.

Thromb Res. 2012 Apr;129(4):e77-82. doi: 10.1016/j.thromres.2011.07.026. Epub 2011 Aug 17.

PMID:
21851967
38.

Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux.

Wolzt M, Samama MM, Kapiotis S, Ogata K, Mendell J, Kunitada S.

Thromb Haemost. 2011 Jun;105(6):1080-90. doi: 10.1160/TH10-11-0705. Epub 2011 May 5.

PMID:
21544313
39.

[Thrombosis and assisted reproductive techniques (ART)].

Conard J, Plu-Bureau G, Horellou MH, Samama MM, Gompel A.

J Mal Vasc. 2011 Jun;36(3):145-54. doi: 10.1016/j.jmv.2010.12.001. Epub 2011 Feb 17. Review. French.

PMID:
21333476
40.

Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment.

Samama MM.

Drugs Aging. 2011 Mar 1;28(3):177-93. doi: 10.2165/11586730-000000000-00000. Review.

PMID:
21329400
41.

Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels.

Jeske WP, Walenga JM, Samama MM, Hoppensteadt D, Mayuga M, Fareed J.

Blood Coagul Fibrinolysis. 2011 Apr;22(3):206-10. doi: 10.1097/MBC.0b013e328343f859.

PMID:
21297455
42.

Laboratory assessment of new anticoagulants.

Samama MM, Guinet C.

Clin Chem Lab Med. 2011 May;49(5):761-72. doi: 10.1515/CCLM.2011.134. Epub 2011 Feb 3. Review.

PMID:
21288169
43.

New antiplatelet agents.

Samama M.

Acta Anaesthesiol Belg. 2010;61(3):127. No abstract available.

PMID:
21268565
44.

[Direct inhibitors of thrombin, hirudin, bivalirudin, and dabigatran etexilate].

Meddahi S, Samama MM.

J Mal Vasc. 2011 Feb;36(1):24-32. doi: 10.1016/j.jmv.2010.11.005. Epub 2011 Jan 15. French.

PMID:
21239127
45.

Interindividual variability of in vitro response to anticoagulants.

Samama MM.

Thromb Res. 2011 Jan;127(1):1. doi: 10.1016/j.thromres.2010.09.018. Epub 2010 Nov 13. No abstract available.

PMID:
21075429
46.

[Two new anticoagulants available in 2010--Dabigatran Etexilate and Rivaroxaban: expected progresses--raised problems].

Samama M, Conard J, Horellou MH, Le Flem L, Guinet C, Depasse F.

Ann Pharm Fr. 2010 Nov;68(6):359-69. doi: 10.1016/j.pharma.2010.08.001. Epub 2010 Oct 29. Review. French.

PMID:
21073994
47.

The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study.

Tripodi A, Chantarangkul V, Guinet C, Samama MM.

J Thromb Haemost. 2011 Jan;9(1):226-8. doi: 10.1111/j.1538-7836.2010.04106.x. No abstract available.

48.

The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.

Samama MM.

Thromb Res. 2011 Jun;127(6):497-504. doi: 10.1016/j.thromres.2010.09.008. Epub 2010 Oct 2. Review.

PMID:
20888031
49.

Assays for measuring rivaroxaban: their suitability and limitations.

Lindhoff-Last E, Samama MM, Ortel TL, Weitz JI, Spiro TE.

Ther Drug Monit. 2010 Dec;32(6):673-9. doi: 10.1097/FTD.0b013e3181f2f264. Review.

PMID:
20844464
50.

Does ambulation modify venous thromboembolism risk in acutely ill medical patients?

Amin AN, Girard F, Samama MM.

Thromb Haemost. 2010 Nov;104(5):955-61. doi: 10.1160/TH10-04-0236. Epub 2010 Sep 13.

PMID:
20838741

Supplemental Content

Loading ...
Support Center